Comparison of aspirin versus aspirin plus clopidogrel for prevention of saphenous vein graft occlusion following coronary artery bypass grafting.

Asan Medical Center0 个研究点目标入组 400 人开始时间: 待定最近更新: 2020年9月7日

适应症

试验速览

暂无简介。

•1) Men or women at least 18 years of age
•2) Patients undergoing CABG with the use of 1 or more SVGs
•3) The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

•1) A known intolerance to a study drug (aspirin, clopidogrel)
•2) Patients who will have valve or aorta surgery simultaneously.
•3) History of hemorrhagic stroke or known structural cerebral vascular lesion (AV malformation, aneurysm, etc)
•4) Patients requiring long-term oral anticoagulants or dual antiplatelet therapy
•5) Persistent thrombocytopenia (platelet count <100,000/?l)
•6) Chronic kidney disease (eGFR<30ml/min/1.73m2)
•7) Inability to undergo coronary computed tomography angiography, in the investigator's opinion, for instance due to severe claustrophobia or contrast allergy
•8) Current treatment for the active cancer
•9) Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.
•10)Unwillingness or inability to comply with the procedures described in this protocol.
•11) Patient’s pregnant or breast-feeding or child-bearing potential.
•12) Patients who had CPCR due to cardiac arrest or ECHMO due to critical heart failure

发起方